Lotia Farrukh Ismat, Lachenal Nathalie, Adenov Malik M, Ahmed Saman, Algozhin Yerkebulan, Coutisson Sylvine, Garavito Epifanio Sánchez, Hewison Catherine, Holtzman David, Huerga Helena, Janmohamed Aleeza, Khan Palwasha Y, Jacques Gamarly Leblanc, Lomtadze Nino, Melikyan Nara, Mitnick Carole D, Mussabekova Gulnaz, Osso Elna, Perea Sara, Putri Fauziah Asnely, Rashidov Mahmud, Rich Michael L, Sakhabutdinova Yekaterina, Seung Kwonjune J, Stambekova Assel, Vásquez Dante Vargas, Franke Molly F, Khan Uzma
Interactive Research and Development Pakistan, Karachi, Pakistan.
Pharmacovigilance Unit, Médecins Sans Frontières, Geneva, Switzerland.
Clin Infect Dis. 2024 Jan 25;78(1):144-148. doi: 10.1093/cid/ciad445.
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.
在43名接受含贝达喹啉和/或德拉马尼的耐多药/利福平耐药结核病（MDR/RR-TB）治疗的孕妇中，98%获得了良好的治疗结局。在31例持续妊娠中，81%分娩活婴，未报告有畸形，68%的新生儿出生体重正常。孕期有效的MDR/RR-TB治疗可改善孕产妇结局，且不损害新生儿。
